Primena intravenskih imunoglobulina kod novorođenčadi sa hemoliznom bolesti i imunskom trombocitopenijom
Sažetak
Uvod/Cilj.
Intravenski imunoglobulini su preparat humanih imunoglobulina G dobijenih iz plazme zdravih davalaca. Mehanizam delovanja intravenskih imunoglobulina veoma je sloћen. Njihova primena je indikovana u lečenju hemolizne bolesti i imunskoj trombocitopeniji novorođenčeta. Cilj rada bio je prikaz sopstvenog iskustva u primeni intravenskih imunoglobulina u grupi terminske novorođenčadi. Metode. Analizirani su anamnestički podaci, klinički nalazi i laboratorijski rezultati 23 novorođenčeta koji su u periodu od 2006. do 2010. dobijali intravenske imunoglobuline tokom hospitalizacije u neonatalnoj intenzivnoj nezi Instituta za majku i dete Srbije „Dr Vukan Čupić“. Rezultati. Kod 11 novorođenčadi indikacija za primenu intravenskih imunoglobulina bila je hemolizna bolest novorođenčeta, dok je 12 novorođenčadi imalo imunsku trombocitopeniju. Kod svih bolesnika primenjena je doza od 1 do 2 g/kg telesne mase intravenskih imunoglobulina. Nisu registrovane komplikacije primenjene terapije. Kod novorođenčadi sa hemoliznom boleљću doљlo je do znatnog sniћenja nivoa bilirubina, љto je omogućilo da najveći broj bolesnika izbegne eksangvinotransfuziju. Primena intravenskih imunoglobulina dovela je do značajnog porasta broja trombocita kod bolesnika sa imunskom trombocitopenijom. Zaključak. Primena intravenskih imunoglobulina vrlo je efikasna za sniћavanje potrebe za eksagvinotransfuzijom, za skraćenje trajanja fototerapije i skraćenju trajanja hospitalizacije kod novorođenčadi sa hemoliznom boleљću. Kod novorođenčadi sa imunskom trombocitopenijom primena intravenskih imunoglobulina dovodi do značajnog porasta broja trombocita, sniћavajući time rizik od potencijalno ozbiljnih komplikacija trombocitopenije.
Reference
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory disease with intravenous immune globulin. N Eng J Med 2001; 345(10): 747−55.
Negl VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine M, et al. Intravenous immunoglobulin: an update of the clinical use and mechanism of action. J Clin Immunol 2007; 27: 233−45.
Provan D, Nkes T, Agrawai S, Winer J, Wood P. Clinical guidelines for immunoglobulinuse. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085235 [published 2011 August 23].
Ohlsson A, Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2010; 3: CDOO1239.
INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous im-munoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial. BMC Pregnancy Childbirth 2008; 8: 52.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114(1): 297−316.
Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002; (3): CD003313.
Gottstein R, Cooke RW. Systemic review of intraveous immu-noglobulin in haemolytic disease of the newborn. Arch Dis Chil Fetal Neonatal Ed 2003; 88(1): F6−10.
Koura HM, Ezz ZM, Ibrahim NA, Motawie AA, Saleh ME. The role of intravenous immunoglobulins in decreasing the need for exchange transfusion in neonates with isoimmune haemolytic jaundice. J App Sci Res 2009; 5(11): 1923−8.
Girish G, Chawla D, Agarwal R, Paul VK, Deorari AK. Efficacy of two dose regimes of intravenous immunoglobulin in Rh haemolytic disease of newborn- a randomized controlled trial. Indian Pediatr 2008; 45(8): 653−9.
Monpoux F, Dageville C, Maillotte AM, De Smet S, Casagrande F, Boutte P. High –dose intravenous immunoglobulin therapy and neonatal jaundice due to red blood cell alloimmunization (French). Arch Pediatr 2009; 16(9): 1289−94. (French)
Smits-Wintjens V, Walther FJ, Lopriore E. Rhesus haemolytic disease of the newborn: postnatal management, associated morbidity and long-term outcome. Semin Fetal Neonatal Med 2008; 13(4): 265−71.
Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala O. Intravenous immunoglobulin G therapy for significant hyperbilirbinemia in ABO haemolytic disease of the newborn. J Matern Fetal Neonatal Med 2004; 16(3): 163−6.
Sato K, Hara T, Kondo T, Iwao H, Honda S, Ueda K. High dose immunoglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Pediatr Scand 1991; 80(2): 163−6.
Ergaz Z, Arad I. Intravenous immunoglobulin therapy in neonatal haemolytic jaundice. J Perinatal Med 1993; 21(3): 183−7.
Voto L, Sexer H, Ferreiro G, Tavosnanska J, Orti J, Mathet E, et al. Neonatal administration of high dose intravenous immu-noglobulin in rhesus haemolytic disease. J Perinat Med 1995: 23(6): 443−51.
Bussel J, Sola-Visner M. Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopenia. Semin Perinatol 2009; 33(1): 35−42.
Johnson J, Ryan G, Al-Musa A, Farkas S, Blanchette VS. Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia. Semin Perinatol 1997; 21(1): 45−52.
Roberts I, Murray N. Neonatal thrombocytopenia. Semin Fetal Neonat Med 2008; 13(4): 256−64.
Kaplan C. Fetal and neonatal alloimmune thrombocytopenia. Orphanet Encyclopedia. Available from: http://www.orpha.net/data/patho/GB/uk-NAIT.pdf [updated 2011 June 6].
Kiefer V, Bassler D, Kroll H, Paes B, Glers G, Ditomasso J, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006, 107(9): 3761−3.
te Pas A, Lopriore E, Van den Akker E, Oepkes Kanhai H, Brand A, et al. Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG. Eur J Pediatr 2007; 166(10): 1057−63.
Ghevaert C, Campbell K, Walton J Smith GA, Allen D, Williamson LM, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2007: 47(5): 901−10.
Ouwehand W, Smith G, Ranasinghe E. Management of severe alloimmune thrombocytopenia in the newborn. Arch Dis Child Fetal Neonatal Ed 2000; 82(3): F173−5.
Bussel J, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev 2008; 22(1): 33−52.
Bussel J, Kaplan C, Mc Farland J. Recommendations for the evaluation and treatment of neonatal autoimmune and alloim-mune thrombocytopenia. The Working Party of Neonatal Imune Thrombocytopenia of the Neonatal Hemostasis Sub-commitee of the ISTH. Thromb Haemost 1991; 65(5): 631−4.